Literature DB >> 18183496

Hyperphosphatemia and nicotinic acid in peritoneal dialysis patients.

Carlos Guido Musso, Maria J Reynaldi, Carolina Aparicio, Silvina Frydenlund, Nora Imperiali, L Algranati.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18183496     DOI： 10.1007/s11255-007-9306-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  2 in total

1.  Extended release nicotinic acid - a novel oral agent for phosphate control.

Authors:  Krishnaswamy Sampathkumar; Manickam Selvam; Yesudas Santhakumari Sooraj; Sankaran Gowthaman; Rajappan Nair Prabha Ajeshkumar
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

Authors:  Yutaka Takahashi; Araki Tanaka; Tsukasa Nakamura; Tsutomu Fukuwatari; Katsumi Shibata; Noriaki Shimada; Isao Ebihara; Hikaru Koide
Journal:  Kidney Int       Date:  2004-03       Impact factor: 10.612
  2 in total
  2 in total

1.  Npt2b deletion attenuates hyperphosphatemia associated with CKD.

Authors:  Susan C Schiavi; Wen Tang; Christina Bracken; Stephen P O'Brien; Wenping Song; Joseph Boulanger; Susan Ryan; Lucy Phillips; Shiguang Liu; Cynthia Arbeeny; Steven Ledbetter; Yves Sabbagh
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

Review 2.  Niacin and analogs for phosphate control in dialysis--perspective from a developing country.

Authors:  Krishnaswamy Sampathkumar
Journal:  Int Urol Nephrol       Date:  2008-11-27       Impact factor: 2.370
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.